NASDAQ:SRNE

Sorrento Therapeutics Competitors

$7.56

+0.14 (+1.89 %)

(As of 04/21/2021 01:17 PM ET)

Add

Compare

Today's Range

$7.35

Now: $7.56▼

$7.76

50-Day Range

$6.93

MA: $8.64▼

$10.40

52-Week Range

$2.18

Now: $7.56▼

$19.39

Volume139,498 shs

Average Volume15.45 million shs

Market Capitalization$2.16 billion

P/E RatioN/A

Dividend YieldN/A

Beta2.7

Sorrento Therapeutics (NASDAQ:SRNE) Vs. FATE, XLRN, HALO, DNLI, VIR, and TWST

Should you be buying SRNE stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Sorrento Therapeutics, including Fate Therapeutics (FATE), Acceleron Pharma (XLRN), Halozyme Therapeutics (HALO), Denali Therapeutics (DNLI), Vir Biotechnology (VIR), and Twist Bioscience (TWST).

Sorrento Therapeutics vs. Fate Therapeutics Stock

Fate Therapeutics (NASDAQ:FATE) and Sorrento Therapeutics (NASDAQ:SRNE) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, analyst recommendations, profitability, institutional ownership and risk.

Insider and Institutional Ownership

99.7% of Fate Therapeutics shares are held by institutional investors. Comparatively, 27.4% of Sorrento Therapeutics shares are held by institutional investors. 21.4% of Fate Therapeutics shares are held by company insiders. Comparatively, 3.4% of Sorrento Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Fate Therapeutics and Sorrento Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Fate Therapeutics	-810.13%	-35.51%	-25.40%
Sorrento Therapeutics	-698.01%	-314.06%	-43.60%

Volatility and Risk

Fate Therapeutics has a beta of 1.88, indicating that its stock price is 88% more volatile than the S&P 500. Comparatively, Sorrento Therapeutics has a beta of 2.7, indicating that its stock price is 170% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and price targets for Fate Therapeutics and Sorrento Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fate Therapeutics	0	4	9	0	2.69
Sorrento Therapeutics	0	0	4	0	3.00

Fate Therapeutics currently has a consensus target price of $108.3125, indicating a potential upside of 31.03%. Sorrento Therapeutics has a consensus target price of $28.75, indicating a potential upside of 280.79%. Given Sorrento Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Sorrento Therapeutics is more favorable than Fate Therapeutics.

Earnings & Valuation

This table compares Fate Therapeutics and Sorrento Therapeutics' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fate Therapeutics	$10.68 million	725.85	$-98,150,000.00	($1.44)	-57.40
Sorrento Therapeutics	$31.43 million	68.62	$-292,070,000.00	($2.12)	-3.56

Fate Therapeutics has higher earnings, but lower revenue than Sorrento Therapeutics. Fate Therapeutics is trading at a lower price-to-earnings ratio than Sorrento Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Fate Therapeutics beats Sorrento Therapeutics on 8 of the 14 factors compared between the two stocks.

Sorrento Therapeutics vs. Acceleron Pharma Stock

Sorrento Therapeutics (NASDAQ:SRNE) and Acceleron Pharma (NASDAQ:XLRN) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, earnings and profitability.

Earnings and Valuation

This table compares Sorrento Therapeutics and Acceleron Pharma's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sorrento Therapeutics	$31.43 million	68.62	$-292,070,000.00	($2.12)	-3.56
Acceleron Pharma	$73.99 million	98.60	$-124,860,000.00	($2.38)	-50.62

Acceleron Pharma has higher revenue and earnings than Sorrento Therapeutics. Acceleron Pharma is trading at a lower price-to-earnings ratio than Sorrento Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Sorrento Therapeutics has a beta of 2.7, suggesting that its stock price is 170% more volatile than the S&P 500. Comparatively, Acceleron Pharma has a beta of 0.59, suggesting that its stock price is 41% less volatile than the S&P 500.

Profitability

This table compares Sorrento Therapeutics and Acceleron Pharma's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sorrento Therapeutics	-698.01%	-314.06%	-43.60%
Acceleron Pharma	-157.84%	-31.62%	-28.11%

Institutional and Insider Ownership

27.4% of Sorrento Therapeutics shares are owned by institutional investors. Comparatively, 79.8% of Acceleron Pharma shares are owned by institutional investors. 3.4% of Sorrento Therapeutics shares are owned by insiders. Comparatively, 2.5% of Acceleron Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Sorrento Therapeutics and Acceleron Pharma, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sorrento Therapeutics	0	0	4	0	3.00
Acceleron Pharma	0	3	10	1	2.86

Sorrento Therapeutics presently has a consensus price target of $28.75, indicating a potential upside of 280.79%. Acceleron Pharma has a consensus price target of $148.2143, indicating a potential upside of 23.02%. Given Sorrento Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Sorrento Therapeutics is more favorable than Acceleron Pharma.

Summary

Acceleron Pharma beats Sorrento Therapeutics on 9 of the 15 factors compared between the two stocks.

Sorrento Therapeutics vs. Halozyme Therapeutics Stock

Sorrento Therapeutics (NASDAQ:SRNE) and Halozyme Therapeutics (NASDAQ:HALO) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, profitability and earnings.

Valuation and Earnings

This table compares Sorrento Therapeutics and Halozyme Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sorrento Therapeutics	$31.43 million	68.62	$-292,070,000.00	($2.12)	-3.56
Halozyme Therapeutics	$195.99 million	35.39	$-72,240,000.00	($0.50)	-96.80

Halozyme Therapeutics has higher revenue and earnings than Sorrento Therapeutics. Halozyme Therapeutics is trading at a lower price-to-earnings ratio than Sorrento Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Sorrento Therapeutics has a beta of 2.7, suggesting that its share price is 170% more volatile than the S&P 500. Comparatively, Halozyme Therapeutics has a beta of 1.77, suggesting that its share price is 77% more volatile than the S&P 500.

Profitability

This table compares Sorrento Therapeutics and Halozyme Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sorrento Therapeutics	-698.01%	-314.06%	-43.60%
Halozyme Therapeutics	10.78%	24.29%	4.08%

Insider & Institutional Ownership

27.4% of Sorrento Therapeutics shares are held by institutional investors. Comparatively, 98.5% of Halozyme Therapeutics shares are held by institutional investors. 3.4% of Sorrento Therapeutics shares are held by insiders. Comparatively, 2.6% of Halozyme Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Sorrento Therapeutics and Halozyme Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sorrento Therapeutics	0	0	4	0	3.00
Halozyme Therapeutics	0	1	9	0	2.90

Sorrento Therapeutics currently has a consensus price target of $28.75, indicating a potential upside of 280.79%. Halozyme Therapeutics has a consensus price target of $42.9167, indicating a potential downside of 11.33%. Given Sorrento Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Sorrento Therapeutics is more favorable than Halozyme Therapeutics.

Summary

Halozyme Therapeutics beats Sorrento Therapeutics on 9 of the 14 factors compared between the two stocks.

Sorrento Therapeutics vs. Denali Therapeutics Stock

Sorrento Therapeutics (NASDAQ:SRNE) and Denali Therapeutics (NASDAQ:DNLI) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, profitability and earnings.

Valuation and Earnings

This table compares Sorrento Therapeutics and Denali Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sorrento Therapeutics	$31.43 million	68.62	$-292,070,000.00	($2.12)	-3.56
Denali Therapeutics	$26.68 million	245.69	$-197,610,000.00	($2.07)	-26.17

Denali Therapeutics has lower revenue, but higher earnings than Sorrento Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Sorrento Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

27.4% of Sorrento Therapeutics shares are held by institutional investors. Comparatively, 68.2% of Denali Therapeutics shares are held by institutional investors. 3.4% of Sorrento Therapeutics shares are held by insiders. Comparatively, 19.3% of Denali Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Sorrento Therapeutics and Denali Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sorrento Therapeutics	0	0	4	0	3.00
Denali Therapeutics	0	1	7	0	2.88

Sorrento Therapeutics currently has a consensus price target of $28.75, indicating a potential upside of 280.79%. Denali Therapeutics has a consensus price target of $75.8571, indicating a potential upside of 40.01%. Given Sorrento Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Sorrento Therapeutics is more favorable than Denali Therapeutics.

Profitability

This table compares Sorrento Therapeutics and Denali Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sorrento Therapeutics	-698.01%	-314.06%	-43.60%
Denali Therapeutics	-968.59%	-39.19%	-30.71%

Volatility and Risk

Sorrento Therapeutics has a beta of 2.7, suggesting that its share price is 170% more volatile than the S&P 500. Comparatively, Denali Therapeutics has a beta of 2, suggesting that its share price is 100% more volatile than the S&P 500.

Summary

Denali Therapeutics beats Sorrento Therapeutics on 8 of the 14 factors compared between the two stocks.

Sorrento Therapeutics vs. Vir Biotechnology Stock

Vir Biotechnology (NASDAQ:VIR) and Sorrento Therapeutics (NASDAQ:SRNE) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, risk, institutional ownership, earnings and analyst recommendations.

Institutional & Insider Ownership

54.5% of Vir Biotechnology shares are owned by institutional investors. Comparatively, 27.4% of Sorrento Therapeutics shares are owned by institutional investors. 37.2% of Vir Biotechnology shares are owned by company insiders. Comparatively, 3.4% of Sorrento Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Vir Biotechnology and Sorrento Therapeutics' revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vir Biotechnology	$8.09 million	747.82	$-174,680,000.00	($5.76)	-8.21
Sorrento Therapeutics	$31.43 million	68.62	$-292,070,000.00	($2.12)	-3.56

Vir Biotechnology has higher earnings, but lower revenue than Sorrento Therapeutics. Vir Biotechnology is trading at a lower price-to-earnings ratio than Sorrento Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Vir Biotechnology has a beta of -0.99, meaning that its share price is 199% less volatile than the S&P 500. Comparatively, Sorrento Therapeutics has a beta of 2.7, meaning that its share price is 170% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and target prices for Vir Biotechnology and Sorrento Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vir Biotechnology	2	0	5	0	2.43
Sorrento Therapeutics	0	0	4	0	3.00

Vir Biotechnology currently has a consensus price target of $66.00, suggesting a potential upside of 39.62%. Sorrento Therapeutics has a consensus price target of $28.75, suggesting a potential upside of 280.79%. Given Sorrento Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Sorrento Therapeutics is more favorable than Vir Biotechnology.

Profitability

This table compares Vir Biotechnology and Sorrento Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vir Biotechnology	-339.61%	-47.11%	-39.44%
Sorrento Therapeutics	-698.01%	-314.06%	-43.60%

Summary

Vir Biotechnology beats Sorrento Therapeutics on 8 of the 14 factors compared between the two stocks.

Sorrento Therapeutics vs. Twist Bioscience Stock

Sorrento Therapeutics (NASDAQ:SRNE) and Twist Bioscience (NASDAQ:TWST) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability and earnings.

Valuation & Earnings

This table compares Sorrento Therapeutics and Twist Bioscience's gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sorrento Therapeutics	$31.43 million	68.62	$-292,070,000.00	($2.12)	-3.56
Twist Bioscience	$90.10 million	70.43	$-139,930,000.00	($3.00)	-43.48

Twist Bioscience has higher revenue and earnings than Sorrento Therapeutics. Twist Bioscience is trading at a lower price-to-earnings ratio than Sorrento Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Sorrento Therapeutics and Twist Bioscience's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sorrento Therapeutics	-698.01%	-314.06%	-43.60%
Twist Bioscience	-155.31%	-44.62%	-35.49%

Analyst Ratings

This is a summary of recent ratings and price targets for Sorrento Therapeutics and Twist Bioscience, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sorrento Therapeutics	0	0	4	0	3.00
Twist Bioscience	1	1	3	0	2.40

Sorrento Therapeutics presently has a consensus target price of $28.75, suggesting a potential upside of 280.79%. Twist Bioscience has a consensus target price of $137.50, suggesting a potential upside of 5.41%. Given Sorrento Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Sorrento Therapeutics is more favorable than Twist Bioscience.

Volatility & Risk

Sorrento Therapeutics has a beta of 2.7, meaning that its stock price is 170% more volatile than the S&P 500. Comparatively, Twist Bioscience has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500.

Insider and Institutional Ownership

27.4% of Sorrento Therapeutics shares are held by institutional investors. Comparatively, 87.9% of Twist Bioscience shares are held by institutional investors. 3.4% of Sorrento Therapeutics shares are held by insiders. Comparatively, 7.0% of Twist Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Twist Bioscience beats Sorrento Therapeutics on 8 of the 14 factors compared between the two stocks.